NasdaqGM - Delayed Quote USD
TriSalus Life Sciences, Inc. (TLSIW)
1.4000
+0.0200
+(1.45%)
As of May 15 at 4:00:00 PM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
29,431
29,431
18,511
12,398
8,401
Cost of Revenue
4,103
4,103
2,605
2,258
1,193
Gross Profit
25,328
25,328
15,906
10,140
7,208
Operating Expense
61,493
61,493
70,381
46,579
31,240
Operating Income
-36,165
-36,165
-54,475
-36,439
-24,032
Net Non Operating Interest Income Expense
-2,686
-2,686
415
179
-1,761
Other Income Expense
8,812
8,812
-5,294
-10,918
-3,049
Pretax Income
-30,039
-30,039
-59,354
-47,178
-28,842
Tax Provision
6
6
9
9
3
Net Income Common Stockholders
-33,233
-33,233
-63,602
-50,016
-28,845
Diluted NI Available to Com Stockholders
-33,233
-33,233
-63,602
-50,016
-28,845
Total Operating Income as Reported
-36,165
-36,165
-54,475
-36,439
-24,032
Total Expenses
65,596
65,596
72,986
48,837
32,433
Net Income from Continuing & Discontinued Operation
-30,045
-30,045
-59,363
-47,187
-28,845
Normalized Income
-37,252.9600
-37,252.9600
-60,119.8200
-45,460.0600
-25,050
Interest Income
404
404
431
180
0
Interest Expense
3,090
3,090
16
1
1,761
Net Interest Income
-2,686
-2,686
415
179
-1,761
EBIT
-26,949
-26,949
-59,338
-47,177
-27,081
EBITDA
-26,205
-26,205
-58,654
-46,779
-26,617
Reconciled Cost of Revenue
4,103
4,103
2,605
2,258
1,193
Reconciled Depreciation
744
744
684
398
464
Net Income from Continuing Operation Net Minority Interest
-30,045
-30,045
-59,363
-47,187
-28,845
Total Unusual Items Excluding Goodwill
9,124
9,124
958
-2,186
-3,795
Total Unusual Items
9,124
9,124
958
-2,186
-3,795
Normalized EBITDA
-35,329
-35,329
-59,612
-44,593
-22,822
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0
Tax Effect of Unusual Items
1,916.0400
1,916.0400
201.1800
-459.0600
0
12/31/2021 - 2/9/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade